Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-α 2b treatment
<p>Abstract</p> <p>Background</p> <p>High-dose interferon-alpha 2b (IFN-α 2b) is the only approved systemic therapy in the United States for the adjuvant treatment of melanoma. The study objective was to explore the immunomodulatory mechanism of action for IFN-α 2b by m...
Main Authors: | Ascierto Paolo A, Napolitano Maria, Celentano Egidio, Simeone Ester, Gentilcore Giusy, Daponte Antonio, Capone Mariaelena, Caracò Corrado, Calemma Rosa, Beneduce Gerardo, Cerrone Margherita, De Rosa Vincenzo, Palmieri Giuseppe, Castello Giuseppe, Kirkwood John M, Marincola Francesco M, Mozzillo Nicola |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-08-01
|
Series: | Journal of Translational Medicine |
Online Access: | http://www.translational-medicine.com/content/8/1/76 |
Similar Items
-
Serial detection of circulating tumour cells by reverse transcriptase-polymerase chain reaction assays is a marker for poor outcome in patients with malignant melanoma
by: Daponte Antonio, et al.
Published: (2006-11-01) -
Effect of dabrafenib on melanoma cell lines harbouring the BRAF<sup><it>V600D/R</it></sup> mutations
by: Gentilcore Giusy, et al.
Published: (2013-01-01) -
NF-κB as potential target in the treatment of melanoma
by: Madonna Gabriele, et al.
Published: (2012-03-01) -
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
by: Mariaelena Capone, et al.
Published: (2018-07-01) -
Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma
by: Mozzillo Nicola, et al.
Published: (2012-06-01)